<!--
Homepage version latest-updates

Instruction:

1. Always use three hashtags (###) to start a section title.

2. Please include an anchor link to the detailed latest updates page in each section title.
   You can click the üîó symbol on detailed latest updates page to find out the corresponding anchor link.
   Please follow the existing sections for the correct format.

3. One paragraph description for each section. The paragraph should contain less than ~200 chars.

4. Dated updates should be listed in descending order.

5. For links from covdb.stanford.edu, please remove the leading "https://covdb.stanford.edu".
   For example, "https://covdb.stanford.edu/page/updates/" should be shorten to "/page/updates/".

6. Try not to include plain links such as [https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044](https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044).
   Please include readable content in the bracket, e.g. [video](https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044).

7. Please do not delete this instruction.

-->
### Database Entries (Jan 05)
Sauer M, Park Y, et int., and Veesler D. [‚ÄúStructural basis for broad coronavirus neutralization.‚Äù](/search/?article=Veesler20) _bioRxiv_, 2020. [doi.org/10.1101/2020.12.29.424482](https://doi.org/10.1101/2020.12.29.424482).
### Database Entries (Jan 05)
Winkler ES, Gilchuk P, et int., and Diamond MS. [‚ÄúHuman neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic protection.‚Äù](/search/?article=Winkler20) _bioRxiv_, 2020. [doi.org/10.1101/2020.12.28.424554](https://doi.org/10.1101/2020.12.28.424554).
### [Clinical Trials (Dec 31)](/page/updates/#clinical.trials)
[2 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-12-31)
### Database Entries (Dec 30)
Ashhurst AS, Tang AH, et int., and Payne RJ. [‚ÄúPotent in vitro anti-SARS-CoV-2 activity by gallinamide A and analogues via inhibition of cathepsin L.‚Äù](/search/?article=Ashhurst20) _bioRxiv_, 2020. [doi.org/10.1101/2020.12.23.424111](https://doi.org/10.1101/2020.12.23.424111).
### Database Entries (Dec 28)
[‚ÄúA Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19.‚Äù](/search/?article=ACTIV-3_LY-CoV55520) New England Journal of Medicine, 2020. [doi.org/10.1056/NEJMoa2033130](https://doi.org/10.1056/NEJMoa2033130).
### Database Entries (Dec 25)
Xie X, Muruato AE, et int., and Shi P. [‚ÄúA nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19.‚Äù](/search/?article=Xie20) _Nature Communications_, 2020. [doi.org/10.1038/s41467-020-19055-7](https://doi.org/10.1038/s41467-020-19055-7). \[[PubMed33060595](https://www.ncbi.nlm.nih.gov/pubmed/33060595/)\] \[[PMC7567097](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567097/)\]
### [Clinical Trials (Dec 24)](/page/updates/#clinical.trials)
[8 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-12-24)
### Database Entries (Dec 18)
Weinreich DM, Sivapalasingam S, et int., and Yancopoulos GD. [‚ÄúREGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.‚Äù](/search/?article=Weinreich20) _The New England journal of medicine_, 2020. [doi.org/10.1056/nejmoa2035002](https://doi.org/10.1056/nejmoa2035002). \[[PubMed33332778](https://www.ncbi.nlm.nih.gov/pubmed/33332778/)\]

### [Clinical Trials (Dec 17)](/page/updates/#clinical.trials)
[9 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-12-17)

### Database Entries (Dec 17)
Eslami G, Mousaviasl S, et int., and Mobarak S. [‚ÄúThe impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19.‚Äù](/search/?article=Eslami20) _Journal of Antimicrobial Chemotherapy_, 2020. [doi.org/10.1093/jac/dkaa331](https://doi.org/10.1093/jac/dkaa331). \[[PubMed32812051](https://www.ncbi.nlm.nih.gov/pubmed/32812051/)\] \[[PMC7529105](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7529105/)\]
### Database Entries (Dec 16)
Hahn F, Wangen C, et int., and Marschall M. [‚ÄúIMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro.‚Äù](/search/?article=Hahn20) _Viruses_, 2020. [doi.org/10.3390/v12121394](https://doi.org/10.3390/v12121394). \[[PubMed33291455](https://www.ncbi.nlm.nih.gov/pubmed/33291455/)\]
### Database Entries (Dec 16)
Painter WP, Holman W, et int., and Painter GR. [‚ÄúHuman Safety, Tolerability, and Pharmacokinetics of a Novel Broad-Spectrum Oral Antiviral Compound, Molnupiravir, with Activity Against SARS-CoV-2.‚Äù](/search/?article=Painter20) _bioRxiv_, 2020. [doi.org/10.1101/2020.12.10.20235747](https://doi.org/10.1101/2020.12.10.20235747).
### Database Entries (Dec 16)
Puhl AC, Fritch EJ, et int., and Ekins S. [‚ÄúRepurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine and Pyronaridine: In vitro Activity Against SARS-CoV-2 and Potential Mechanisms.‚Äù](/search/?article=Puhl20) _bioRxiv_, 2020. [doi.org/10.1101/2020.12.01.407361](https://doi.org/10.1101/2020.12.01.407361). \[[PubMed33299990](https://www.ncbi.nlm.nih.gov/pubmed/33299990/)\] \[[PMC7724658](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724658/)\]
### Database Entries (Dec 16)
Cox RM, Wolf JD, and Plemper RK. [‚ÄúTherapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets.‚Äù](/search/?article=Cox20) _Nature Microbiology_, 2020. [doi.org/10.1038/s41564-020-00835-2](https://doi.org/10.1038/s41564-020-00835-2). \[[PubMed33273742](https://www.ncbi.nlm.nih.gov/pubmed/33273742/)\]
### Database Entries (Dec 14)
Calistri A, Luganini A, et int., and Parolin C. [‚ÄúThe new generation hDHODH inhibitor MEDS433 hinders the in vitro replication of SARS-CoV-2.‚Äù](/search/?article=Calistri20) _bioRxiv_, 2020. [doi.org/10.1101/2020.12.06.412759](https://doi.org/10.1101/2020.12.06.412759).
### Database Entries (Dec 14)
Tree JA, Turnbull JE, et int., and Carroll MW. [‚ÄúUnfractionated heparin inhibits live wild‚Äêtype SARS‚ÄêCoV‚Äê2 cell infectivity at therapeutically relevant concentrations.‚Äù](/search/?article=Tree20) _British Journal of Pharmacology_, 2020. [doi.org/10.1111/bph.15304](https://doi.org/10.1111/bph.15304). \[[PubMed33125711](https://www.ncbi.nlm.nih.gov/pubmed/33125711/)\]

### Database Entries (Dec 11)
Abdelnabi R, Foo CS, et int., and Neyts J. [‚ÄúMolnupiravir (EIDD-2801) inhibits SARS-CoV2 replication in Syrian hamsters model.‚Äù](/search/?article=Abdelnabi20) _bioRxiv_, 2020. [doi.org/10.1101/2020.12.10.419242](https://doi.org/10.1101/2020.12.10.419242).
### Database Entries (Dec 11)
Arabi YM, Shalhoub S, et int., and Fowler R. [‚ÄúRibavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study.‚Äù](/search/?article=Arabi19)¬†_Clinical Infectious Diseases_,¬†2019.¬†[doi.org/10.1093/cid/ciz544](https://doi.org/10.1093/cid/ciz544).¬†\[[PubMed31925415](https://www.ncbi.nlm.nih.gov/pubmed/31925415/)\]¬†\[[PMC7108209](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108209/)\]
### Database Entries (Dec 11)
Hassan AO, Case JB, et int., and Diamond MS. [‚ÄúA SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies.‚Äù](/search/?article=Hassan20) _Cell_, 2020. [doi.org/10.1016/j.cell.2020.06.011](https://doi.org/10.1016/j.cell.2020.06.011). \[[PubMed32553273](https://www.ncbi.nlm.nih.gov/pubmed/32553273/)\] \[[PMC7284254](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284254/)\]
### Database Entries (Dec 11)
Johnson RF, Bagci U, et int., and Marasco WA. [‚Äú3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012.‚Äù](/search/?article=Johnson16) _Virology_, 2016. [doi.org/10.1016/j.virol.2016.01.004](https://doi.org/10.1016/j.virol.2016.01.004). \[[PubMed26828465](https://www.ncbi.nlm.nih.gov/pubmed/26828465/)\] \[[PMC4769911](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769911/)\]
### Database Entries (Dec 11)
Kawase M, Shirato K, et int., and Matsuyama S. [‚ÄúSimultaneous Treatment of Human Bronchial Epithelial Cells with Serine and Cysteine Protease Inhibitors Prevents Severe Acute Respiratory Syndrome Coronavirus Entry.‚Äù](/search/?article=Kawase12) _Journal of Virology_, 2012. [doi.org/10.1128/jvi.00094-12](https://doi.org/10.1128/jvi.00094-12). \[[PubMed22496216](https://www.ncbi.nlm.nih.gov/pubmed/22496216/)\] \[[PMC3393535](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3393535/)\]
### Database Entries (Dec 11)
Lu L, Liu Q, et int., and Jiang S. [‚ÄúStructure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor.‚Äù](/search/?article=Lu14) _Nature Communications_, 2014. [doi.org/10.1038/ncomms4067](https://doi.org/10.1038/ncomms4067). \[[PubMed24473083](https://www.ncbi.nlm.nih.gov/pubmed/24473083/)\] \[[PMC7091805](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091805/)\]
### Database Entries (Dec 11)
O'Keefe BR, Giomarelli B, et int., and McCray PB. [‚ÄúBroad-Spectrum In Vitro Activity and In Vivo Efficacy of the Antiviral Protein Griffithsin against Emerging Viruses of the Family Coronaviridae.‚Äù](/search/?article=OKeefe10) _Journal of Virology_, 2009. [doi.org/10.1128/jvi.02322-09](https://doi.org/10.1128/jvi.02322-09). \[[PubMed20032190](https://www.ncbi.nlm.nih.gov/pubmed/20032190/)\] \[[PMC2820936](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2820936/)\]
### Database Entries (Dec 11)
Vatansever EC, Yang K, et int., and Liu WR. [‚ÄúBepridil is potent against SARS-CoV-2 In Vitro.‚Äù](/search/?article=Vatansever20) _bioRxiv_, 2020. [doi.org/10.1101/2020.05.23.112235](https://doi.org/10.1101/2020.05.23.112235). \[[PubMed32511370](https://www.ncbi.nlm.nih.gov/pubmed/32511370/)\] \[[PMC7263498](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263498/)\]
### [Clinical Trials (Dec 10)](/page/updates/#clinical.trials)
[4 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-12-10)

### Database Entries (Dec 09)
Sch√§fer A, Muecksch F, et int., and Sheahan TP. [‚ÄúAntibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo.‚Äù](/search/?article=Schafer20) _Journal of Experimental Medicine_, 2020. [doi.org/10.1084/jem.20201993](https://doi.org/10.1084/jem.20201993). \[[PubMed33211088](https://www.ncbi.nlm.nih.gov/pubmed/33211088/)\] \[[PMC7673958](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673958/)\]
### Database Entries (Dec 09)
H√∂rnich BF, Gro√ükopf AK, et int., and Hahn AS. [‚ÄúSARS-CoV-2 and SARS-CoV spike-mediated cell-cell fusion differ in the requirements for receptor expression and proteolytic activation and are not inhibited by Bromhexine.‚Äù](/search/?article=Hornich20) _bioRxiv_, 2020. [doi.org/10.1101/2020.07.25.221135](https://doi.org/10.1101/2020.07.25.221135).
### Database Entries (Dec 04)
Ar√©valo A, Pagotto R, et int., and Crispo M. [‚ÄúIvermectin reduces coronavirus infection in vivo: a mouse experimental model.‚Äù](/search/?article=Arevalo20) _bioRxiv_, 2020. [doi.org/10.1101/2020.11.02.363242](https://doi.org/10.1101/2020.11.02.363242).
### Database Entries (Dec 04)
Clausen TM, Sandoval DR, et int., and Esko JD. [‚ÄúSARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2.‚Äù](/search/?article=Clausen20) _Cell_, 2020. [doi.org/10.1016/j.cell.2020.09.033](https://doi.org/10.1016/j.cell.2020.09.033). \[[PubMed32970989](https://www.ncbi.nlm.nih.gov/pubmed/32970989/)\] \[[PMC7489987](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7489987/)\]
### Database Entries (Dec 04)
Kumar R, Khandelwal N, et int., and Kumar N. [‚ÄúEmetine as an antiviral agent suppresses SARS-CoV-2 replication by inhibitinginteraction of viral mRNAwith eIF4E: An in vitro study.‚Äù](/search/?article=Kumar20) _bioRxiv_, 2020. [doi.org/10.1101/2020.11.29.401984](https://doi.org/10.1101/2020.11.29.401984).
### [Clinical Trials (Dec 03)](/page/updates/#clinical.trials)
[17 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-12-03)
### Database Entries (Dec 03)
Outlaw VK, Bovier FT, et int., and Porotto M. [‚ÄúInhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain.‚Äù](/search/?article=Outlaw20) _mBio_, 2020. [doi.org/10.1128/mbio.01935-20](https://doi.org/10.1128/mbio.01935-20). \[[PubMed33082259](https://www.ncbi.nlm.nih.gov/pubmed/33082259/)\] \[[PMC7587434](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7587434/)\]
### Database Entries (Dec 03)
Udwadia ZF, Singh P, et int., and Tandon M. [‚ÄúEfficacy and Safety of Favipiravir, an Oral RNA-Dependent RNA Polymerase Inhibitor, in Mild-to-Moderate COVID-19: A Randomized, Comparative, Open-Label, Multicenter, Phase 3 Clinical Trial.‚Äù](/search/?article=Udwadia20) _International Journal of Infectious Diseases_, 2020. [doi.org/10.1016/j.ijid.2020.11.142](https://doi.org/10.1016/j.ijid.2020.11.142). \[[PubMed33212256](https://www.ncbi.nlm.nih.gov/pubmed/33212256/)\] \[[PMC7668212](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668212/)\]
